Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis
AIM: Treatment of chronic kidney disease (CKD) includes parenteral iron therapy, and these infusions can lead to iron overload. Secondary iron overload is typically treated with iron chelators, of which deferasirox is one of the most promising. However, it has not been studied in patients with CKD...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Wiley-Blackwell Publishing Asia
2013
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/20.500.11937/11024 |